Naproxen and Esomeprazole and Vizimpro

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

By reducing the acidity level in the stomach, esomeprazole may interfere with the absorption of dacomitinib and reduce its effectiveness. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact or interact to a lesser extent. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs. When a single 45 mg dose of dacomitinib was coadministered with rabeprazole (40 mg once daily for 7 days) in 24 healthy subjects, dacomitinib peak plasma concentration (Cmax) and systemic exposure (AUC 0 to 96 hours) decreased by approximately 51% and 39%, respectively, compared to dacomitinib administered alone. By contrast, administration of dacomitinib with a local antacid (aluminum hydroxide-magnesium hydroxide 400 mg-400 mg/5 mL) did not cause clinically relevant changes in dacomitinib concentrations. The lack of a significant interaction may be due to the shorter duration of action of antacids relative to PPIs. The interaction has not been studied with H2-receptor antagonists. Based on pooled data in clinical study patients, H2-receptor antagonists had no apparent effect on steady-state trough concentration of dacomitinib.

MANAGEMENT: Concomitant use of dacomitinib with PPIs should generally be avoided. If acid suppression therapy is required, locally-acting antacids or H2-receptor antagonists may be considered. The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists.

Naproxen and Esomeprazole

Generic Name: esomeprazole / naproxen

Brand name: Vimovo

Synonyms: Esomeprazole and naproxen

What is Naproxen and Esomeprazole?

Vizimpro

Generic Name: dacomitinib

Brand name: Vizimpro

Synonyms: n.a.

What is Vizimpro?